Dissertations / Theses on the topic 'HIV gag protein p17'

The human immunodeficiency virus type-1 matrix (HIV-1 MA) is best described as a multi-functional, structural protein. However, the multitude of functional activities ascribed to this viral component is not nearly as interesting as are its seemingly paradoxical and opposing roles during the viral life cycle. At the time of virus infection, HIV-1 MA remains associated with the reverse transcription complex, in which viral nucleic acids are synthesized, and facilitates its translocation to the host cell nucleus (Bukrinsky, Sharova et al. 1992; Bukrinsky, Sharova et al. 1993). This activity of MA has been proposed to form the basis for the infection of non-dividing cells (Bukrinsky, Haggerty et al. 1993). An interaction between the C-terminally phosphorylated form of MA and HIV-1 integrase, an integral component of the complex, was initially proposed to mediate this association (Gallay, Swingler et al. 1995; Gallay, Swingler et al. 1995). However, conditions which promote dissociation of integrase from the reverse transcription complex do not reduce MA association (Miller, Farnet et al. 1997). The possibility of a direct interaction between MA and the viral genome is discussed in Chapter III. The nucleophilic nature of HIV-1 MA is paradoxical with its reported activity in targeting the viral precursor proteins to the cytoplasmic membrane (Krausslich and Welker 1996), during the particle production phase of the viral life cycle. Furthermore, MA when expressed in the absence of other viral proteins exhibits a cytoplasmic localization (Fouchier, Meyer et al. 1997); a result which does not support a nuclear translocation role for this protein. The work presented here resolves this seemingly controversial issue. We demonstrate that MA exhibits a strong nuclear export activity. This newly discovered activity is designed to effectively counteract the protein's innate nucleophilic nature, thus maintaining a cytoplasmic localization. The nuclear export function of MA is sensitive to changes within the conformation of the protein as C- and N-terminal deletions, as well as point mutations in the protein, abolish the activity. Furthermore, the export activity is mediated by the Crm1 NES receptor (Fornerod, Ohno et al. 1997; Fukuda, Asano et al. 1997; Ossareh-Nazari, Bachelerie et al. 1997) despite the lack of a leucine-rich export signal within the matrix coding region. Therefore, the interaction between matrix protein and Crm1 is most likely to be mediated by another, perhaps cellular, protein. Any changes in matrix structure may lead to the disruption of this protein-protein interaction. We discuss a model implicating a phosphorylation event in the inactivation of this nuclear export signal. An even more fascinating issue regards the role of this nuclear export activity, during the viral life cycle, and is detailed in Chapter II. In short, mutations in MA which impair its nuclear export activity result in nuclear accumulation of the precursor Gag polyprotein (Pr55) and the nucleocapsid-associated viral genomic RNA. As a result, non-infectious virions deficient in genomic viral RNA are produced. Therefore, drugs designed to block this export activity can undermine the carefully orchestrated course of events during HIV replication and can shut down the growth of the virus.

HIV-associated neurocognitive disorder in HIV patients substantially reduces their quality of life. We hypothesised that the HIV matrix protein, p17, already linked to tumour promotion and aberrant angiogenesis could contribute to neurological decline and cellular dysfunction within the brain and aimed here to confirm this. The experimental design was formulated to test the direct neurodegenerative capacity of p17 protein on relevant brain cells, both in vitro and in vivo to ascertain the potential of p17 within the brain to encourage neurodegenerative processes and to confirm that p17 was present in the brain of infected individuals. In vitro cell culture experiments identified cellular signalling induced by p17 within brain cells. I characterised the effects of hippocampal CA1 injection of p17 on histological appearance of brain sections following the analysis of the animals by our collaborators- behaviour, cognitive function and memory. Histological expression of p17 in tissue from three HIV patients who died from stroke was determined. Cell signalling pathways potentially associated with neurodegenerative signalling or aberrant angiogenesis were studied by Western blotting. p17 increased phosphorylation of ERK1/2, IRS-1 and EGFR in endothelial cells, blocking cell signalling and angiogenesis via an inhibitor peptide of EGFR. In neurons, p17 induced the phosphorylation of ERK1/2, Tau, FAK and IRS-1. Cognitive function and behavioural deficiencies after p17 injection were mimicked by demonstration that it localised in ventricular tracts, cortical microvessels and neurons. p17 formed β-amyloid/prion-like protein fibrillar aggregates, suggesting a pathogenic direct capability similar to that of β-amyloid. P17 was also identified in macrophages, microvessels, neurons and amyloid-beta (Aβ)-positive plaques in HIV-infected human brain sections. This work supports the involvement of p17 in initiating/perpetuating neurodegenerative pathophysiology associated with cognitive decline. Key words: P17, HIV-associated neurocognitive decline, angiogenesis, fibrillary, signalling.

The process of HIV-1 particle production is a multi-step process directed by the viral structural protein Gag. As Gag is the only viral protein required to form virus-like particles, it presents a viable target for anti-viral therapeutics of which there are currently none. Although the functions of Gag during the particle assembly process have been well characterized, one of the least known parts of the assembly process is how Gag is targeted to the site of virus assembly. Two main virus assembly sites have been identified in cells that support HIV-1 replication: the plasma membrane or multivesicular bodies (MVBs). However the mechanism by which Gag is targeted to either of these sites remains unknown. The δ subunit of Adaptor Protein Complex 3 has previously been identified as a cellular co-factor for HIV-1 Gag and was reported to mediate Gag trafficking to MVBs, providing a mechanism for Gag targeting to this assembly site. Additionally, AP-3δ was reported to be required for HIV-1 production, suggesting that Gag to MVB targeting is also required for HIV-1 production. The work presented in this thesis further investigates the role of AP-3δ in Gag trafficking to MVBs and its role in HIV-1 production in previously unexplored host environments. Through the use of RNA interference-mediated depletion of AP-3δ, we determined that AP-3δ is dispensible for virus replication in infected HeLa cells, chronically infected HeLa-LAV cells and infected primary human monocyte-derived macrophages. We concomitantly disrupted AP-3 function by disrupting its association with membranes and observed no effect on virus production. Collectively, these results demonstrate that AP-3δ is not required for HIV-1 replication. However, AP-3δ was demonstrated to be required for Gag targeting to MVBs thus presenting a new model for the function of AP-3δ in the context of HIV-1 replication.

La protéine multidomaine Pr55Gag de VIH-1 joue un rôle crucial dans les étapes finales de la réplication virale, notamment lors de la reconnaissance et la sélection de l’ARN génomique ainsi que lors de la production de nouvelles particules virales. Outre son rôle structural, Pr55Gag chaperonne aussi les séquences d’acides nucléiques, une propriété cruciale pour la dimérisation de l’ARN génomique et l’hybridation de l’amorce ARNt à l’ARN génomique. Des partenaires cellulaires comme la protéine ribosomale RPL7 sont supposées être recrutées par Pr55Gag afin d’augmenter son potentiel chaperon. Afin d’étudier le mécanisme d’hybridation des acides nucléiques par Gag et RPL7, nous avons examiné leur effet sur la réaction d’hybridation entre dTAR, la version ADN de l’élément de transactivation virale et sa séquence complémentaire cTAR. Nos résultats révèlent que Gag et RPL7 présentent des mécanismes différents pour promouvoir l’hybridation cTAR/dTAR. Utilisés de concert, RPL7 peut aider Gag à chaperonner des séquences stables de l’ARN génomique que Gag seule pourrait difficilement chaperonner. Ce renforcement par RPL7 de l’activité chaperonne de Gag jouerait un rôle critique dans l’assemblage du virus
The multidomain Pr55 Gag protein of HIV-1 plays a crucial role during late stages of viral replication, notably for the recognition and selection of genomic RNA as well as for the production of new viral particles. In addition to its structural role, Pr55 Gag also chaperones nucleic acid sequences, a property which is crucial for genomic RNA dimerization and annealing of the primer tRNA to the genomic RNA. Cellular partners like ribosomal protein RPL7 are thought to be recruited by Pr55 Gag to enhance its chaperoning potential. To investigate the nucleic acid annealing mechanism of Gag and RPL7, we examined their effect on the annealing reaction between dTAR, the DNA version of the viral transactivation element and its complementary cTAR sequence taken as relevant model HIV-1 sequences. Our data show that Gag and RPL7 exhibit different mechanisms for promoting the cTAR/dTAR annealing. When used together, RPL7 can help Gag to chaperone stable sequences of the genomic RNA that Gag would hardly be able to chaperone alone. This RPL7-driven boost in Gag chaperone activity is thought to be critical in the viral assembly process

La polyprotéine Gag du VIH-1 qui contient quatre principaux domaines (Matrix (MA), capside (CA), nucléocapside (NC), et P6) est l’orchestrateur privilégié de l'assemblage du virus HIV-1, assemblage qui a lieu pendant la phase tardive de la réplication. Il est bien connu que Gag interagit avec les lipides de la membrane plasmique de la cellule hôte et s’auto-assemble sur le feuillet interne de cette dernière afin de générer de nouvelles particules virales. Le bourgeonnement de ces particules virales hors de la cellule hôte est décrit comme étant dépendant de la machinerie cellulaire ESCRT. Différentes études structurales, fonctionnelles ainsi que des simulations de dynamique gros grain ont montré que la liaison de Gag à la membrane est médiée par une interaction duale. Une spécifique de nature éléctrostatique, qui associe une région hautement basique (HBR) du domaine MA de Gag au lipide acide,phosphatidyl inositol biphosphate (PI(4,5)P2) du feuillet interne de la membrane plasmique. Une de type hydrophobe, qui consiste en l’insertion du myristate de Gag dans la membrane plasmique. Savoir si Gag reconnait spécifiquement des domaines lipidiques pré-existants de type « rafts » ou si, au contraire, Gag tri ses lipides et les réorganise latéralement afin d’optimiser sa multimérisation et son bourgeonnement est une question à la fois fondamentale et d’actualité en virologie.Durant ma thèse, j’ai vérifié l’existence de la seconde hypothèse en utilisant des membranes modèles contenant du PI (4,5) P2 marqué de façon fluorescente et différent mutants et produits de la protéine Gag non-myristoylée. Ces expériences ont montré de fortes affinités de ces protéines pour les membranes contenant du PI (4,5) P2. S’appuyant sur les propriétés d’auto-extinction de fluorescence du marqueur choisit et à l’aide des différents variants de la protéine Gag, j'ai pu montré que la multimérisation de Gag génère l’existence de nanodomaines contenant du PI (4, 5) P2 et du cholestérol, la sphingomyéline étant au contraire exclue de ces domaines. En marquant la protéine Gag par un autre fluorophore, j’ai pu montrer par microscopie optique sur des vésicules lipidiques géantes (GUVs) que la protéine Gag partitionnait préférablement dans des microdomaines lipidiques de type liquide désordonnés (Ld). Par la suite, j’ai testé la capacité de la protéine Gag d’induire la formation de vésicules sur des membranes modèles (Bicouches supportés et GUVs) contenant du PI(4,5) P2 et de la phosphatidyl sérine (PS). En utilisant une microbalance à cristal de quartz (QCM-D) et des techniques de microscopie de fluorescence, j’ai suivi l'auto-assemblage de Gag dans le temps et ai montré que la protéine Gag était suffisante pour générer une courbure de la membrane et libérer des vésicules lipidiques. Grâce à différents produits de maturation de cette protéine, j’ai montré que la présence des domaines MA et CA est suffisante pour produire ces vésicules.L’ensemble de ces résultats suggèrent que la liaison et la multimérisation de la protéine Gag ne se produit pas dans des domaines lipidiques préexistants de type « raft », mais, au contraire, que la liaison et multimérisation de la protéine Gag génère l’existence de domaines lipidiques enrichis en PI (4,5) P2 et en cholestérol. La générescence de ces domaines lipidiques pourrait participer à la courbure de la membrane plasmique nécessaire au bourgeonnement du virus
Gag polyprotein of HIV-1 is made of four main domains Matrix (MA), Capsid (CA), Nucleocapsid (NC), and P6 and is the prime orchestrator of virus assembly that occurs during the late phase of replication. It is well known that Gag interacts with host cell lipids and self-assemble along the inner-leaflet of the plasma membrane in order to generate virus like particles (VLPs). Budding of these VLPs out of the living cell is described to be ESCRT dependent. Structural, functional and simulation based studies has shown that Gag membrane binding is mediated by a bipartite interaction. One specific electrostatic interaction, between the highly basic region (HBR) of its MA domain and the host cell acidic lipid phosphatidyl inositol bisphophate (PI(4,5)P2), plus a hydrophobic interaction through Gag’s myristate insertion in the plasma membrane. It is still an opened question whether Gag would specifically recognize pre-existing lipid domains such as rafts to optimize its multimerization or, on the contrary, would reorganize lipids during its multimerization. During my Ph.D. I explored the second hypothesis using purified myr(-) Gag protein and model membranes containing fluorescently labelled PI(4,5)P2.Bonding experiments have shown strong affinities of these purified proteins towards PI(4,5)P2 containing lipid bilayers. Using PI(4,5)P2 fluorescence self-quenching properties, I found that multimerization Gag generates PI(4,5)P2/Cholesterol enriched nanoclusters. On the opposite, sphingomyelin was excluded from these nanoclusters. In addition to this, using a fluorescently labelled myr(-) Gag, I have observed its preferable partitioning into lipid disordered (Ld) phases of giant unilamellar vesicles (GUVs). Further, possibility of whether HIV-1 Gag alone, as a minimal system, can induce the formation of vesicles on PI(4,5)P2/PS containing supported lipid bilayers (SLBs) & GUVs was tested. Using quartz crystal microbalance (QCM-D) and fluorescence microscopy techniques, I monitored the self-assembly of HIV-1 Gag with time and found that Gag was sufficient to generate membrane curvature and vesicle release. Moreover, using mutants of this protein, I found that having MA and CA domain is enough for Gag to produce vesicle like structures. Taken together, these results suggest that binding and multimerization of Gag protein does not occur in pre-existing lipid domains (such as “rafts”) but this multimerization is more likely to induce PI(4,5)P2/Cholesterol nanoclusters. This nanophase separation could locally play a role in the membrane curvature needed for the budding of the virus

Retroviruses express their repertoire of products from a single primary transcript. However, it appears that the default condition for posttranscriptional processing in a normal cell is to completely splice any intron-containing transcripts. Consequently, the dilemma for the retroviruses is how to export the full length, unspliced and partially spliced transcript which both code for structural proteins, as well as serves as the genome to be packaged into mature virus particles. Many retroviruses (HIV-1, HTLV-l, EIAV, visna) exploit posttranscriptional mechanisms, by which their intron-containing mRNAs circumvent nuclear retention, and are exported to the cytoplasm. For example, HIV-1 RNAs contain at least one functional intron that must enter the cytoplasm to act as templates for the synthesis of proteins. HIV-l regulates expression of its genome through the interaction of a virally encoded trans-acting factor, Rev, with a cis-acting Rev responsive element (RRE). Rev binds unspliced and singly spliced nuclear transcripts containing the RE and shuttles them into the cytoplasm. Other retroviruses (MPMV, SRV) lack Rev-like trans-acting viral proteins. Their transcripts contain a cis-acting element, termed the constitutive transport element (CTE), that allows transport of intron-containing mRNAs. CTE-like elements have also been identified in DNA viruses (Hepatitis B, HSV~1). Retroviral CTEs have been shown to be able to substitute for the Rev/RRE system to allow efficient regulatory control of HIV expression. Although a number of studies have examined what cellular cofactors are involved in Rev/RRE and CTE-mediated transport, it is not clear if common cellular cofactor(s) exist. In these studies we have used a transfection/competition assay to investigate whether Rev/RRE-, SRVCTE~, and MPMVCTE-containing transcripts utilize similar cofactors for nucleocytoplasmic transport. Coexpression of gagMPMVCTE and pCwtRev at various concentrations in the same cell demonstrated that Rev inhibited CTE- mediated transport from the nucleus. Using the same assay we further demonstrated that GTE-mediated export was not inhibited by cotransfection with a pCΔRev(-) mutant clone, a Rev point mutant clone, or luciferase, a non-specific marker protein. Our data suggest that this inhibition is specific for Rev, and for a specific region of the Rev protein. We propose that Rev and the CTEs interact with a common cellular cofactor(s), or that Rev directly interacts with the CTEs.

O HIV-1 é o agente etiológico da síndrome da imunodeficiência adquirida (AIDS) e o HTLV-I da leucemia/linfoma de célula T no adulto (ATL) e da paraparesia espástica tropical ou mielopatia associada ao HTLV (HAM/TSP), principalmente. Ambos são retrovírus com genoma RNA e possuem o gene gag que codifica as proteínas p24 (HIV-1 e HTLV-1) e p19 (HTLV-1) que formam o capsídeo e a matriz do vírus, respectivamente, e o gene env que codifica as proteínas gp41 e gp120 (HIV-1) e gp21 e gp46 (HTLV-1) que compõem o envelope viral. Os primeiros anticorpos produzidos nas infecções por ambos os vírus são destinados a essas proteínas e os diferentes testes diagnósticos disponíveis no mercado usam uma combinação dessas proteínas virais. O diagnóstico precoce é de extrema importância para o controle da epidemia, tratamento dos indivíduos e planejamento dos gastos com saúde pública. Os kits diagnósticos usados em laboratórios clínicos, bancos de sangue e hospitais brasileiros para o diagnóstico destas viroses são na sua maioria de empresas estrangeiras e o Brasil despende milhares de reais importando esses materiais. No Brasil, há a necessidade e incentivo para a produção de sistemas de diagnóstico com tecnologia nacional. Neste trabalho, os genes das proteínas p24, gp41 e gp120 do HIV-1 e p19 do HTLV-1 foram clonados com sucesso em diferentes vetores e em diferentes linhagens de E. coli, porém essas proteínas não foram expressas. As proteínas gp21, p24 e gp46 do HTLV-1 foram produzidas em bactérias BL21(DE3) com vetor pET28a(+). Essas três proteínas foram solubilizadas dos corpos de inclusão, purificadas por IMAC e identificadas pelas técnicas de Western Blotting e por espectrometria de massas. As proteínas recombinantes gp21, p24 e gp46 foram reconhecidas pelos soros de indivíduos com HTLV-1 e não foram reconhecidas por soros de indivíduos com HIV-1 e saudáveis, o que confere a elas especificidade e grande potencial diagnóstico. Os resultados deste trabalho são os primeiros passos para atingir o objetivo maior de produzir todas as sete proteínas em maior escala e, por fim, chegar a produção de um kit diagnóstico sensível, específico e barato com tecnologia nacional, diminuindo os gastos com a importação destes produtos e fomentando a indústria biotecnológica nacional.
HIV-1 is the etiologic agent of acquired immunodeficiency syndrome (AIDS) and HTLV-I is the cause of adult T-cell leukemia/lymphoma (ATL) and HTLV-I-associated myelopathy or tropical spastic paraparesis (HAM/TSP). Both are retroviruses with RNA genome and possess the gene gag and env. The gag gene encodes for p24 protein (HTLV-1 and HIV-1) and p19 (HTLV-1) forming the viral capsid and matrix, respectively, and the env gene encodes for proteins gp120 and gp41 (HIV-1) and gp21 and gp46 (HTLV-1) making the viral envelope. The first antibodies produced in infections by both viruses are against these proteins and the various diagnostic tests on the market use a combination of those viral proteins. Early diagnosis is extremely important to control the epidemia, treatment of individuals and planning of public health expenditures. The diagnostic kits used in clinical laboratories, blood banks and in Brazilian hospitals for the diagnosis of these viruses are mostly from foreign companies. Brazil spends thousands of reais importing these materials. In Brazil, there is a need and incentive for the production of diagnostic systems with national technology. In this study, the genes of p24, gp41 and gp120 of HIV-1 and p19 of HTLV-1 have been successfully cloned in different vectors and different strains of E. coli, but these proteins were not expressed. The proteins gp21, gp46 and p24 of HTLV-1 were produced in bacteria BL21 (DE3) with vector pET28a (+). These three proteins were solubilized from inclusion bodies, purified by IMAC and identified by Western blotting techniques and mass spectrometry. The recombinant proteins gp21, p24 and gp46 were recognized by sera from patients with HTLV-1 and were not recognized by sera from individuals with HIV-1 and healthy people, which gives them great specificity and diagnostic potential. These results are the first steps to achieve the ultimate goal of producing all seven proteins on a larger scale and finally get the production of a diagnostic kit sensitive, specific and cheap with national technology, reducing spending on imports of these products and fostering the national biotechnology industry.

Depuis sa découverte il y a plus de 30 ans, le Virus de l’Immunodéficience Humaine est à l’origine d’une importante mortalité dans le monde. De par la difficulté de tester l’efficacité de formulations thérapeutiques et/ou vaccinales directement chez l’homme, des études d’infections modèles du VIH, comme celle du Virus de l’Immunodéficience Féline (FIV), ont été entreprises ces dernières années. Au-delà de son intérêt vétérinaire, l’étude du FIV représente un avantage important pour trouver un moyen de contrôler les infections par les lentivirus tel que le VIH. Elle peut permettre de développer et surtout de tester l’efficacité des vaccins et/ou thérapies spécifiques chez le chat, dont le SIDA mime les symptômes et les modifications hématologiques rencontrés chez l’homme. Ce manuscrit s’est intéressé à l’étude structurale de deux familles de protéines virales de ces virus, les protéines lentivirales précoces (protéine Tat du VIH) et tardives (domaines Capside CA et Matrice MA de Gag du FIV). L’étude structurale de ces protéines et leur compréhension fonctionnelle au sein de l’hôte pourront à l’avenir ouvrir de nouvelles voies thérapeutiques et/ou vaccinales contre les lentivirus, palliant ainsi les problèmes existants de résistances virales
Since its discovery 30 years ago, the Human Immunodeficiency Virus is the cause of an important mortality worldwide. Because of the difficulty to test the efficiency of therapeutical and/or vaccinal formulations directly in humans, studies of models of HIV infections, such as the Feline Immunodeficiency Virus (FIV), have been performed in recent years. In addition to its veterinary interest, the study of FIV is an important issue to find a way to control infections by lentiviruses such as HIV. It can help to develop and test the efficiency of specific therapies and/or vaccines for cats, where AIDS mimics the symptoms and hematologic changes observed in humans. This manuscript describes the structural study of two types of viral proteins of these viruses, early lentiviral proteins (HIV Tat protein) and late lentiviral proteins (CA capsid and MA Matrix domains of FIV Gag). The structural study of these proteins and their functional understanding into the host will open new therapeutic and/or vaccine strategies against these lentiviruses in the future, in order to overcome the existing problems of viral resistance

La sélection de l’ARNg des rétrovirus repose sur des interactions entre le domaine nucléocapside (NC) du précurseur Gag et des régions de l’ARN viral appelées ψ (ou Psi) localisées dans la région 5’ non traduite (5’-UTR) de l’ARNg et/ou dans le début du gène gag.Malgré des nombreuses études, les mécanismes moléculaires gouvernant l’incorporation de l’ARNg dans les particules virales en cours d’assemblage sont encore mal compris. La protéine Gag est notoirement sensible à la protéolyse et la plupart des études ont été menées avec une Gag dépourvue du domaine p6 (GagΔp6) qui ne reflètepas correctement les propriétés de fixation de la protéine Gag entière à l’ARNg. Les travaux réalisés aux cours de cette thèse nous ont permis de montrer que Pr55Gag et ses produits de maturation NCp15 et NCp7 sont capables de distinguer l’ARNg du VIH-1 des ARN viraux épissés. La stabilisation des formes dimériques ou la perturbation des interactions à longue distance n’ont aucune influence sur la reconnaissance spécifique de Gag pour l’ARNg. Par des expériences de mutagénèse dirigée et de compétition, nous avons montré non seulement que la dimérisation de l’ARNg et le motif SL1 (surtout sa boucle interne) joue un rôle crucial pour la fixation de Gag mais aussi que l’intégrité de la région Psi est indispensable pour une fixation optimale. Ces résultats nous ont amené à déterminer plus précisément l’empreinte de Gag sur l’ARNg et les résidus requis pour la fixation de Gag qui on confirmé le rôle crucial de SL1 comme le siganl major pour la reconnaissance spécifique de l’ARNg par le pr55Gag
Packaging of HIV-1 genomic RNA (gRNA) is a highly regulated and selective process that leads to prefrential selection and packaging of dimeric gRNA from a cellular medium containing a large excess of cellular and spliced viral mRNAs. This event underlies interaction between the nucleocapsid domain in the context of the uncleaved Gag precursor and a Packaging signal located in the 5’ untranslated region (5’ UTR) of the gRNA and/or the beginning of gag gene. Despite a considerable effort, the molecular mechanisms beyond the selective encapsidation of HIV-1 gRNA is still unknown. To address this, we first characterized the relative affinities of Pr55gag to various HIV-1 RNA fragments (spliced and unspliced) by biochemical and spectroscopic approaches which all revealed that Pr55gag exhibits a higher binding affinity for viral gRNA than for viral spliced species. Interestingly, we noticed that Pr55Gag, through its nucleic acid chaperone activity, was able to stabilize the dimeric form of almost all viral RNA species (spliced and unspliced) suggesting that RNA dimermaturation does not allow the gRNA discrimination. Further characterization of specific Gag binding sites to short RNA fragments corresponding to the minimal packaging signal by competition experiments, inhibition of Gag/RNA interaction by antisense oligo-deoxynucleotides, as well as the detection of Pr55Gag RNA binding sites on gRNA by enzymatic and chemical footprinting confirmed the crucial role of SL1 (or DIS) as a specific binding site for Pr55Gag. Taken together, our results strongly suggest that SL1 and/or RNA dimerization is a specific recognition signal for Pr55Gag to specifically select and probably induce HIV-1 gRNA packaging

APOBEC3 (A3) proteins are a family of host-encoded cytidine deaminases that protect against retroviruses and other viral intruders. Retroviruses, unlike other viruses, are able to integrate their genomic proviral DNA within hours of entering host cells. A3 proteins hinder retroviral infectivity by editing retroviral replication intermediates, as well as by inhibiting retroviral replication and integration through deamination-independent methods. These proteins thus constitute the first line of immune defense against endogenous and exogenous retroviral pathogens. The overall goal of my Master's project was to better understand the critical role A3 proteins play in restricting inter- and intra-host transmission of retroviruses. There are two specific aspects that I focused on: first, investigating the role of mouse APOBEC3 (mA3) in limiting the zoonotic transmission of murine leukemia retroviruses (MLVs) in a rural environment; second, to identify the molecular features in MLVs that confer susceptibility or resistance to deamination by mA3. For the first part of my project, we collected blood samples from dairy and production cattle from four different geographical locations across Canada. We then designed a novel PCR screening strategy targeting conserved genetic regions in MLVs and Mouse Mammary Tumor Virus (MMTV) and MMTV-like betaretroviruses. Our results indicate that 4% of animals were positive for MLV and 2% were positive for MMTV. Despite crossing the species barrier by gaining entry into bovine cells, our study also demonstrates that the bovine A3 protein is able to potently inhibit the spread of these murine retroviruses in vitro. The next question we asked was whether mA3 could also mutate and restrict murine endogenous retroviruses and thereby partake in limiting zoonotic transmission. Moloney MLV and AKV MLV are two highly homologous murine gammaretroviruses with opposite sensitivities to restriction by mA3: MoMLV is resistant to restriction and deamination while AKV is sensitive to both. Design of MoMLV/AKV hybrid viruses enabled us to map the region of mA3 resistance to the region encoding the glyco-Gag accessory protein. Site-directed mutagenesis then allowed us to correlate the number of N-linked glycosylation sites with the level of resistance to deamination by mA3. Our results suggest that Gag glycosylation is a possible viral defence mechanism that arose to counteract the evolutionary pressure imposed by mA3. Overall, my projects show the important role A3 proteins play in intrinsic immunity, whether defending the host from foreign retroviral invaders or endogenous retroviral foes.

碩士
國立臺灣大學
醫事技術學研究所
87
It has been almost two decades since the first discovery of human immunodeficiency virus type 1 (HIV-1). However, the efficient way to control the HIV-1 infection infection is still lacking. Control of the HIV-1 dissemination is thought to be the most important work in public health. Detection of HIV-1 infection is one of the control measure. The development of highly efficient and accurate diagnostic tests for detection of HIV-1 infction is very important. Because of the genetic diver-sity of HIV-1, it would be necessary and important to develop a local diagnostic kit. It has been reported that high titers of antibodies against HIV-1 viral capsid proteins, p17 and p24, are induced after HIV-1 infection. However, the proportion of the HIV-1 infected individuals with anti-p17 antibodies was varied from 30﹪to 95﹪according to different reports. In this study, the p17 genes of the HIV-1 with different subtypes in Taiwan were analyzed and compared, the p17 proteins of different subtypes were expressed. The full-length p17 genes were amplified by polymerase chain reaction and sequenced by the auto-sequencing method. Compari-son of the nucleotide sequences showed that the p17 genes were very similar among the virus strains with the same env subtype. The p17 genes of the strains with different env subtypes were more divergent and clustered into different groups in the phylo-genetic tree. The p17 subtypes were comparable with env sub-types. The deduced amino acids sequences were also aligned. Distinct variations among the strains with different subtypes could be observed in the two sites of potential antigenic epitope. The p17 genes of the strains of subtypes A, B, C, E, and G were cloned into expression vector pRSET. The expression of the recombinant p17 protein was induced by adding IPTG in the E.coli expression system. Proteins of 23-24 KDa were expressed as revealed by SDS-polyacryl-amide gel electrophoresis. The p17 proteins of subtype B and E were further confirmed by the re-activity with anti-p17 monoclonal antibodies in Western blot analysis, although subtype E p17 was reactive in very low in-tensity. The subtype B p17 was also expressed in higher amount and purified by the cobalt column. Purified p17 was used for detection of anti-p17 antibodies present in HIV-1 positive plasma. Preliminary results showed that anti-p17 antibodies could be detected in aboult 48﹪of these HIV-1 infected in-dividuals. In summary, the p17 proteins of different subtypes were successfully expressed. These proteins will be potentially useful as diagnostic antigens. The reactivity of the p17 proteins of different subtypes with the plasma from various subtype infections need to be further studied.

碩士
高雄師範大學
生物科技系
98
Flagellin, a toll-like receptor (TLR)-5 ligand, can be acted as an adjuvant to produce cytokine cascade responses linking activation of innative and acquired immunity. Since the flagellin of Burkholderia pseudomallei exist the epitopes (LQRIRQLAVQ) of this ligand, the recombinant flagellin of the bacteria was used as adjuvant for pVAX1/gag DNA vaccination. Subsequent to intramuscular (i.m.) and subcutaneous (s.c.) immunization, the immunogencitiy for Balb/c mice was evaluated. As a control, pVAX1/gag DNA was injected alone. After 8 weeks, IgG antibodies specific to gag protein was produced as 1.5 fold higher as controls. Moreover, spleen cells received from immunized mice were rapidly proliferated after stimulating synthetic gag epitopes (AAMQMLKDTINEEAA and EPFRDYVDRF) for 72 h. Whereas, IFN--secreting cells in spleen cells supplementing with synthetic gag epitopes were significantly increased as compared to controls (p<0.05). Results indicated that immunogenicity for Balb/c mice was improved after immunizing with recombinant flagellin and pVAX1/gag DNA.

Chemokines are small immune system proteins mediating leukocyte migration and activation, and are important in many aspects of health and diseases. Some chemokines also have the ability to block HIV-1 infection by binding to the HIV-1 co-receptors CCR5 (CC chemokine receptor 5) and CXCR4 (CXC chemokine receptor 4). The first part of this work is to determine the mechanism of action of a human herpesvirus-8 encoded viral chemokine analog vMIP-II (viral macrophage inflammatory protein-II) by characterizing its interactions with endothelial surface glycosaminoglycans (GAGs) and cell surface receptors. Nuclear magnetic resonance (NMR), mutagenesis and molecular-docking were conducted and results show that vMIP-II tightly binds glycosaminoglycans using residues distributed along one face of the protein, such as R18, R46 and R48, and that there is a shift in the GAG binding site between the monomer and dimer form of vMIP-II where the N-terminus is involved in GAG binding for the dimer. This study, for the first time, provides a model that explains the mechanism of how quaternary structure affects chemokine-GAG binding. Mutagenesis and competition binding assays were conducted to study the receptor-binding mechanism of vMIP-II. Preliminary results suggest that vMIP-II uses the same positively charged binding surface comprising R18, K45, R46 and R48 to interact with the negatively charged N-termini of CCR5 and CXCR4. NMR studies on how vMIP-II interacts with N-terminal peptides of CCR5 and CXCR4 is on-going. The second part of this work was to rationally design HIV-1 entry inhibitors based on our knowledge of the mechanisms of chemokine-receptor binding and HIV-1 cell entry. We successfully designed two chimeric HIV entry inhibitors composed of CCR5-targeting RANTES variants (5P12-RANTES and 5P14-RANTES) linked to a gp41 targeting C-peptide, C37. In in vitro assays, chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed the highest anti-viral potency yet published with IC50 values as low as 0.001 nM against certain virus strains. On human peripheral blood mononuclear cells, the chimeric inhibitors also exhibited very strong inhibition against R5-tropic and X4-tropic viruses, with IC50 values as low as 0.015 nM and 0.44 nM, respectively. A clear delivery mechanism was observed and characterized. These fully recombinant inhibitors can be easily produced at low cost and are excellent candidates for HIV microbicides.